Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Saito, Ryuta
EF-41, NCT06556563: /KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma	Recruiting	3	741	Europe, US, RoW	Optune® device, TTFields, Temozolomide, Pembrolizumab, Placebo	NovoCure GmbH, Merck Sharp & Dohme LLC	Glioblastoma	04/29	04/29
RE-GEND, NCT02761070: Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III	Active, not recruiting	3	146	Japan	Temozolomide, Temodar, Temodal, Bevacizumab, Avastin	Kyorin University, Japan Clinical Oncology Group	Glioblastoma, Recurrence, Progression	11/25	11/25
NCT06413706: A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy	Recruiting	2	45	Europe, Japan, US, RoW	Abemaciclib, LY2835219, Temozolomide	Eli Lilly and Company	Glioma	11/27	02/28
OKADA, Keiko
ACTION, NCT05580562: ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the Study) Jan 2026 - Dec 2026: Final data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma Jan 2025 - Mar 2025: Interim data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma	Recruiting	3	450	Europe, Canada, Japan, US, RoW	Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo, Placebo	Chimerix	H3 K27M, Glioma	08/26	08/26
NCT06413706: A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy	Recruiting	2	45	Europe, Japan, US, RoW	Abemaciclib, LY2835219, Temozolomide	Eli Lilly and Company	Glioma	11/27	02/28

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Saito, Ryuta
EF-41, NCT06556563: /KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma	Recruiting	3	741	Europe, US, RoW	Optune® device, TTFields, Temozolomide, Pembrolizumab, Placebo	NovoCure GmbH, Merck Sharp & Dohme LLC	Glioblastoma	04/29	04/29
RE-GEND, NCT02761070: Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III	Active, not recruiting	3	146	Japan	Temozolomide, Temodar, Temodal, Bevacizumab, Avastin	Kyorin University, Japan Clinical Oncology Group	Glioblastoma, Recurrence, Progression	11/25	11/25
NCT06413706: A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy	Recruiting	2	45	Europe, Japan, US, RoW	Abemaciclib, LY2835219, Temozolomide	Eli Lilly and Company	Glioma	11/27	02/28
OKADA, Keiko
ACTION, NCT05580562: ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the Study) Jan 2026 - Dec 2026: Final data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma Jan 2025 - Mar 2025: Interim data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma	Recruiting	3	450	Europe, Canada, Japan, US, RoW	Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo, Placebo	Chimerix	H3 K27M, Glioma	08/26	08/26
NCT06413706: A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy	Recruiting	2	45	Europe, Japan, US, RoW	Abemaciclib, LY2835219, Temozolomide	Eli Lilly and Company	Glioma	11/27	02/28